Oxervate Den Europæiske Union - dansk - EMA (European Medicines Agency)

oxervate

dompe farmaceutici s.p.a. - recombinant human nerve growth factor - keratitis - oftalmologiske - behandling af moderat (vedvarende epiteldefekt) eller alvorligt (hornhindeår) neurotrofisk keratitis hos voksne.

Regranex Den Europæiske Union - dansk - EMA (European Medicines Agency)

regranex

janssen-cilag international nv - becaplermin - wound healing; skin ulcer - præparater til behandling af sår og sår - regranex angives i forening med andre gode sår pleje foranstaltninger, at fremme granulering og dermed heling af fuld-tykkelse, neuropatiske, kronisk, diabetisk sår mindre end eller lig til 5 cm2.

Forcaltonin Den Europæiske Union - dansk - EMA (European Medicines Agency)

forcaltonin

unigene uk ltd. - recombinant salmon calcitonin - hypercalcemia; osteitis deformans; bone resorption - calciumhomeostase - calcitonin er indiceret til forebyggelse af akut tab af knoglemasse på grund af pludselig stilstand som hos patienter med recentosteoporotic fracturespaget er diseasehypercalcaemia af malignitet.

Strangvac Den Europæiske Union - dansk - EMA (European Medicines Agency)

strangvac

intervacc ab - recombinant streptococcus equi protein cce, recombinant streptococcus equi protein eq85, recombinant streptococcus equi protein idee - immunologier til hovdyr - heste - for the active immunisation to reduce clinical signs and the number of abscesses in acute stage of infection with s. equi.

Letifend Den Europæiske Union - dansk - EMA (European Medicines Agency)

letifend

leti pharma, s.l.u. - recombinant protein q from leishmania infantum mon-1 - inaktiverede bakterielle vacciner (herunder mycoplasma, toxoid og chlamydia) - hunde - til aktiv immunisering af hunde fra 6 måneder for at reducere risikoen for at udvikle et klinisk tilfælde af leishmaniasis.

Shingrix Den Europæiske Union - dansk - EMA (European Medicines Agency)

shingrix

glaxosmithkline biologicals sa - recombinant varicella zoster virus glycoprotein e - herpes zoster - vacciner - shingrix is indicated for prevention of herpes zoster (hz) and post-herpetic neuralgia (phn), in:adults 50 years of age or older;adults 18 years of age or older at increased risk of hz. brug af shingrix bør være i overensstemmelse med de officielle anbefalinger.

Zabdeno Den Europæiske Union - dansk - EMA (European Medicines Agency)

zabdeno

janssen-cilag international n.v.    - recombinant adenovirus type 26 (ad26) encoding the glycoprotein (gp) of the ebola virus zaire (zebov) mayinga strain - hæmoragisk feber, ebola - vacciner - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

Mvabea Den Europæiske Union - dansk - EMA (European Medicines Agency)

mvabea

janssen-cilag international n.v.    - recombinant modified vaccinia ankara bavarian nordic virus encoding the: ebola virus zaire (zebov) mayinga strain glycoprotein (gp); ebola virus sudan gulu strain gp; ebola virus taï forest strain nucleoprotein and the marburg virus musoke strain gp - hæmoragisk feber, ebola - vacciner - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

Vectormune FP ILT Den Europæiske Union - dansk - EMA (European Medicines Agency)

vectormune fp ilt

ceva-phylaxia co. ltd. - recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus, live - kylling - for active immunisation of chickens from 8 weeks of age in order to reduce the skin lesions due to fowlpox and to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis.

Arexvy Den Europæiske Union - dansk - EMA (European Medicines Agency)

arexvy

glaxosmithkline biologicals s.a.  - respiratory syncytial virus recombinant glycoprotein f stabilised in the pre-fusion conformation (rsvpref3) produced in chinese hamster ovary (cho) cells by recombinant dna technology - respiratoriske syncytiale virusinfektioner - vacciner - arexvy is indicated for active immunisation for the prevention of lower respiratory tract disease (lrtd) caused by respiratory syncytial virus in adults 60 years of age and older. brug af denne vaccine bør være i overensstemmelse med de officielle anbefalinger.